Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1559-1564

  Thorat, Dhanashri ^a   Sahu, Asutosh ^a   Behera, Reeti ^a,d   Lohite, Kirti ^b   Deshmukh, Sanjay ^b   Mane, Anupama ^b   Karnik, Swapnil ^b   Doke, Suhaschandra ^c   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b Grant Medical Foundation   (India)

^c Institute for Advanced Computing and Life Sciences   (India)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer subtypes; Estrogen receptor; Human epidermal growth factor receptor type 2; Invasive ductal carcinoma; Progesterone receptor; TNM staging

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OSTEOPONTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION;

EID: 84886800484     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1600     Document Type: Article

References (42)

1. Murthy NS, Chaudhry K, Nadayil D, Agarwal UK and Saxena S: Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer 46: 73-74, 2009.
2. Sengupta A: The emergence of the menopause in India. Climacteric 6: 92-95, 2003.
3. Kapur P, Sinha B and Pereira BM: Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause 16: 378-384, 2009.
4. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006.
5. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM and Hogan BL: Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 101: 1468-1478, 1998.
6. Sodek J, Ganss B and McKee MD: Osteopontin. Crit Rev Oral Biol Med 11: 279-303, 2000.
7. Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11: 81-90, 2007.
8. Ahmed M, Behera R, Chakraborty G, et al: Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 15: 1113-1126, 2011.
9. Rudland PS, Platt-Higgins A, El-Tanani M, et al: Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417-3427, 2002.
10. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830, 2006.
11. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B and Weber GF: Osteopontin-c is a selective marker for breast cancer. Int J Cancer 122: 889-897, 2008.
12. Henry NL and Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring and treatment of primary and metastatic breast cancer. Oncologist 11: 541-552, 2006.
13. Clark GM: Prognostic and predictive factors. In: Diseases of the Breast. Harris JR, Lippman ME, Morrow M and Osborne CK (eds). Lippinscott Williams and Wilkins, Philadelphia, pp489-514, 2000.
14. Andre F and Pusztai L: Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol 3: 621-632, 2006.
15. Chandrasekharan NV and Simmons DL: The cyclooxygenases. Genome Biol 5: 241, 2004.
16. Ramsay RG, Ciznadija D, Vanevski M and Mantamadiotis T: Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int J Immunopathol Pharmacol 16: S59-S67, 2003.
17. Sarkar FH, Adsule S, Li Y and Padhye S: Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 7: 599-608, 2007.
18. Kis B, Snipes JA, Isse T, Nagy K and Busija DW: Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab 23: 1287-1292, 2003.
19. Ristimäki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002.
20. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429, 2004.
21. Shim V, Gauthier ML, Sudilovsky D, et al: Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 63: 2347-2350, 2003.
22. Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434, 2002.
23. Davies G, Salter J, Hills M, Martin LA, Sacks N and Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9: 2651-2656, 2003.
24. Denkert C, Winzer KJ, Müller BM, et al: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97: 2978-2987, 2003.
25. Shim JY, An HJ, Lee YH, Kim SK, Lee KP and Lee KS: Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 16: 1199-1204, 2003.
26. Tan KB, Yong WP and Putti TC: Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 44: 24-28, 2004.
27. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F and Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914-1921, 1989.
28. Greene FL, Page DL and Fleming ID (eds): AJCC Cancer Staging Manual, 6th edition. Springer, New York, NY, 2002.
29. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200-206, 1993.
30. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
31. Glass AG, Lacey JV Jr, Carreon JD and Hoover RN: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152-1161, 2007.
32. Ravdin PM, Cronin KA, Howlader N, et al: The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670-1674, 2007.
33. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006.
34. Dolled-Filhart M, Rydén L, Cregger M, Jirstrom K, Harigopal M, Camp RL and Rimm DL: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12: 6459-6468, 2006.
35. Liu R, Wang X, Chen GY, et al: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226, 2007.
36. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423, 2003.
37. Sørlie T, Perou CM, Fan C, et al: Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 5: 2914-2918, 2006.
38. Van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
39. Wang Y, Klijn JG, Zhang Y, et al: Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
40. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H and van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65, 2007.
41. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
42. Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49: 3104-3108, 1989.